financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Lifts Opinion On Mccormick & Company, Incorporated To Buy From Hold
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Lifts Opinion On Mccormick & Company, Incorporated To Buy From Hold
Mar 26, 2024 8:35 AM

11:05 AM EDT, 03/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target by $12 to $85, 27x our FY 25 (Nov.) EPS of $3.16 (up from $2.96; FY 24 up to $2.88 from $2.81) vs. the 30x five-year average forward P/E. FQ1 (Feb-Q) adj-EPS of $0.63 (+7% Y/Y) beat by $0.06 on revenues of $1,603M (+2% Y/Y), $51M above consensus. MKC saw a sequential improvement in volume sales (-1% Y/Y vs. -3% Y/Y in FQ4), which we expect will continue this year, especially if MKC regains some of the lost distribution it experienced over the last few years. MKC is also investing in marketing and innovation and looking to narrow price gaps to store brands. Gross margins grew 140 bps Y/Y to 37.4%, but due to SG&A de-leverage (from higher marketing), operating margins only grew 30 bps Y/Y to 14.8%. We should see stronger margins in F2H 24. MKC kept its guidance unchanged, but will likely raise it next quarter, in our opinion. We believe MKC is on track to return to double-digit EPS growth next fiscal year (FY 25), as this fiscal year (FY 24) is expected to be a heavy investment year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved